Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
R Torrisi, L Baglietto, H Johansson, G Veronesi, B Bonanni, A Guerrieri-Gonzaga, B Ballardini, A Decensi
British Journal of Cancer | Published : 2001
The effect on the IGF system of 60 mg and 600 mg daily of raloxifene administered for 2 weeks prior to surgery was investigated in 37 postmenopausal women with breast cancer. Raloxifene significantly decreased insulin-like growth factor (IGF-I) as compared to placebo (P < 0.05) with no dose-response relationship. No significant change was observed in IGFBP-3, while the IGF-I/IGFBP-3 molar ratio was decreased by treatment, with a statistically significant effect only for the higher dose. Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention.